Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

Diabetic Nephropathy Clinical Trial

Official title:
A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine whether the combination with ramipril and clopidogrel leads to further improvement of endothelial function, reduction of oxidative stress and reduction of vascular inflammation, compared with ramipril monotherapy, in patients with Diabetes Mellitus type 2 and diabetic nephropathy.

Clinical Trial Description

- Cardiovascular disease is the leading cause of deaths in diabetic population with diabetic nephropathy.

- Pharmacologic therapy for patients with diabetes and hypertension should be with a regimen that includes either an angiotensin-converting-enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB)

- Diabetic patients at increased cardiovascular risk should receive an antiplatelet agent for primary prevention.

Methods:

An open label,randomized, two period cross-over design study, involving patients with type 2 diabetes and diabetic nephropathy. After a 4 weeks wash out period for ACE inhibitors or Angiotensin receptor blockers (week 0, baseline) 60 patients will be randomized to receive ramipril(10 mg) only or ramipril (10 mg) and clopidogrel (75mg) for 12 weeks exchanging their treatment for a further 12 weeks, after a 2 week wash out period for clopidogrel. Patients will be examined and measurements will be taken at baseline (week 0), and at the end of 12, 14, and 26 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01743014
Study type	Interventional
Source	AHEPA University Hospital
Contact	Fotios S Iliadis, Lecturer of Internal Medicine
Phone	+306974960728
Email	iliadis@med.auth.gr
Status	Recruiting
Phase	Phase 4
Start date	July 2012
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04562025` - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy	N/A
Not yet recruiting	`NCT03658317` - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy	N/A
Recruiting	`NCT02501772` - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy	N/A
Completed	`NCT02251067` - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients	Phase 2
Completed	`NCT02829177` - Microalbuminuria and Allopurinol in Type 1 Diabetes	Phase 4
Completed	`NCT02276196` - Effect of LIXIsenatide on the Renal System	Phase 4
Completed	`NCT01440257` - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria	Phase 2
Active, not recruiting	`NCT01273675` - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00317954` - Spironolactone in Diabetic Nephropathy	Phase 4
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting	`NCT05061459` - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed	`NCT01935167` - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01673204` - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy	Phase 4
Completed	`NCT01726816` - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01458158` - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease	N/A
Completed	`NCT01476501` - Vitamin D Supplementation in Diabetic Nephropathy	Phase 2
Completed	`NCT01447147` - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy	Phase 2
Completed	`NCT01003236` - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy	Phase 2
Completed	`NCT00535925` - Nephropathy In Type 2 Diabetes and Cardio-renal Events	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.